Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus FOAMCOAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus FOAMCOAT.
BENZAMYCIN vs FOAMCOAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic